LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Teva Pharmaceutical Industries Ltd.

Затворен

СекторЗдравеопазване

17.74 2.96

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.23

Максимум

17.82

Ключови измерители

By Trading Economics

Приходи

495M

220M

Продажби

-338M

3.9B

EPS

0.52

Марж на печалбата

5.654

Служители

37,000

EBITDA

502M

763M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+39.13% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

996M

20B

Предишно отваряне

14.78

Предишно затваряне

17.74

Настроения в новините

By Acuity

15%

85%

22 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.12.2024 г., 19:39 ч. UTC

Значими двигатели на пазара

Correction to Teva Articles

17.12.2024 г., 16:24 ч. UTC

Значими двигатели на пазара

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

7.05.2025 г., 17:01 ч. UTC

Топ новини

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

17.12.2024 г., 16:14 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Affirm, and More -- Barrons.com

17.12.2024 г., 13:51 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Red Cat, and More -- Barrons.com

23.11.2024 г., 12:00 ч. UTC

Топ новини

Emerging-Markets Stocks Have Rarely Been So Hated. It's Time To Buy -- WSJ

22.08.2024 г., 05:30 ч. UTC

Топ новини

Generic Weight-Loss Drugs Won't Come for Years -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Teva Pharmaceutical Industries Ltd. Прогноза

Ценова цел

By TipRanks

39.13% нагоре

12-месечна прогноза

Среден 24 USD  39.13%

Висок 30 USD

Нисък 20 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Teva Pharmaceutical Industries Ltd. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

15.58 / N/AПодкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

22 / 380 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.